Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The World Health Organization (WHO) has officially named the disease caused by the new coronavirus, initially identified in Wuhan, China, as Covid-19.

Chinese authorities first reported a case of pneumonia with an unknown cause in Wuhan to the WHO China office on 31 December.

As more cases emerged, the cause was identified as a novel coronavirus, temporarily named 2019-nCoV or Wuhan coronavirus, in some cases.

The name Covid-19 will avoid the use of other inaccurate names and any references to a geographic location, an animal, an individual or group of people, said WHO director-general Tedros Adhanom Ghebreyesus.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A statement from WHO reads: “Having a name matters to prevent the use of other names that can be inaccurate or stigmatising. It also gives us a standard format to use for any future coronavirus outbreaks.”

The virus has now spread to 25 more countries, leading to a total of 1,115 deaths and more than 45,100 cases, as of the end of 11 February. WHO declared the coronavirus outbreak as a public health emergency of international concern on 30 January.

On 11 February, WHO began its two-day forum to identify knowledge gaps and research priorities to control the spread of Covid-19 epidemic.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact